The demand for weight loss medications like Ozempic, Rybelsus, Wegovy, and Mounjaro has skyrocketed, driven largely by social media. These drugs have shown unprecedented success in weight management, leading to supply shortages. The recent approval of Eli Lilly’s Zepbound—essentially Mounjaro rebranded for weight loss—is expected to further increase demand. To manage supply, Novo Nordisk, the manufacturer of Ozempic, Wegovy, and Rybelsus, has deliberately restricted new starter doses of Wegovy to ensure that current users can maintain their treatment despite ongoing production limitations.
The Role of Compounding Pharmacies
Compounding pharmacies, regulated by state pharmacy boards, create customized versions of medications to meet individual patient needs. They can modify drugs by altering ingredients to avoid allergens, improving taste, adjusting dosage forms (e.g., from tablets to liquids), or producing strengths unavailable in brand-name options.
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, Compounding pharmacies prepare customized medications pursuant to a valid prescription for an individual patient.. However, unlike drug manufacturers, they are not required to seek FDA approval or oversight for safety and efficacy.
Compounded Drugs and Shortages
When medications appear on the FDA drug shortage list, compounding pharmacies may prepare patient-specific compounded medications pursuant to a valid prescription and in accordance with applicable federal and state regulations. Currently, semaglutide—the active ingredient in Ozempic and Wegovy—remains in short supply due to overwhelming demand, impacting both the medication and its auto-injector pen. While tirzepatide, found in Mounjaro and Zepbound, has also faced shortages for diabetes patients, Eli Lilly reports that supply is improving. However, the FDA must still confirm whether availability meets demand before removing it from the shortage list.
Compounded medications are prepared by a licensed pharmacy pursuant to a valid prescription for an individual patient. Compounded medications are not reviewed or approved by the U.S. Food and Drug Administration (FDA).
13462 FM Rd 529 Ste 200,
Houston, Texas 77041
Email: Shahad@mykaduceus.com
Mon-Fri: 9 AM – 6 PM
Saturday: Closed
Sunday: Closed
Copyright 2025 | All Rights Reserved | www.MyKaduceus.com
Jurisdictions & Licensure: Kaduceus Pharmacy is licensed by the Texas State Board of Pharmacy and operates in full compliance with applicable federal and state pharmacy regulations. Prescriptions are dispensed only to patients located in jurisdictions where dispensing and shipment are permitted under applicable law. All orders undergo a compliance review to verify state-specific licensure requirements prior to fulfillment. Medications will not be dispensed or shipped to jurisdictions where the pharmacy is not authorized to do so. For questions regarding state availability, please contact our support team prior to placing an order.
This language reflects Texas as the primary state of licensure and clearly communicates that all dispensing and shipping activity is subject to state-specific compliance verification.